Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03005119
Other study ID # CS-101
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received December 25, 2016
Last updated September 26, 2017
Start date March 1, 2018
Est. completion date December 2018

Study information

Verified date September 2017
Source PhytoTech Therapeutics, Ltd.
Contact Hagit Sacks
Phone +972 3 6449599
Email hsacks@mmjphytotech.com.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety and tolerability of oral administration of PTL201 for relief of spasticity-related symptoms in 70 MS patients and to evaluate the efficacy of oral administration of PTL201 in relief of spasticity-related symptoms in MS patients. The pharmacokinetics of PTL201 in comparison to buccally administered Sativex will be evaluated in sub-study prior to the efficacy study.


Description:

The study will be comprised of the following parts:

1. Pharmacokinetics (PK) sub-study:

A 7-day baseline observation period. Randomized cross-over treatments (Sativex, PTL201), performed at minimum 7-day washout.

Follow up - one week after the last dosing session.

2. Efficacy study:

A 7-day baseline observation period. Single-blind responder phase - 4 weeks. Randomized, double-blind, placebo-controlled treatment phase - 4 weeks Follow up - two weeks.

Subjects participating in the pharmacokinetic sub-study will be allowed to participate in the efficacy study and will not be required to repeat the 7-day observation period of the efficacy study.

Doses will be titrated over a one-week period until reaching maximum tolerated dose (MTD) for each participant The MTD will be self administered for three weeks thereafter. Participants demonstrating response to treatment will continue self administering daily PTL201 treatment or placebo, for an additional four weeks. Participants will keep a daily diary.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 70
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Patient (male or female), age 18-65 years

2. Definite diagnosis of MS, according to McDonald 2010 criteria, at least six months prior to enrollment, with MS associated spasticity for at least 3 months prior to enrollment

1. Patients suffer from moderate to-severe MS-associated spasticity (=4 sNRS), with no adequate response to traditional antispastic medications

2. EDSS score: 4 = EDSS = 6; functional motor score =3.0 Safety, tolerability and efficacy of PTL201 in reducing multiple sclerosis-associated spasticity-related symptoms

3. Moderate to severe spasticity in at least two districts of upper and/or lower limbs

3. Anti-spasticity agent(s) and/or disease-modifying medications maintained at a stable dose for 30 days prior to and throughout the study

4. Patients able to self-score spasticity

5. Absence of clinical or neuroradiological relapses from at least three months prior to study entry

6. Willingness and ability to provide written informed consent

7. Willingness and ability to comply with all study requirements

8. Inclusion criteria for placebo-controlled treatment phase:

No major protocol violations were recorded for the patient in the responder phase and at least 20% improvement in sNRS

Exclusion Criteria:

1. Concomitant disease or disorder with spasticity-like symptoms or that may influence the subject's level of spasticity, or medical history suggesting that relapse/remission is likely to recur during the study or expected to influence spasticity

2. Currently using or used cannabis or cannabinoid-based medications within 30 days of study entry and is unwilling to abstain from using them for the duration of the study.

3. Concurrent significant psychiatric, renal, hepatic,cardiovascular or convulsive disorders

4. History or immediate family history of schizophrenia, other psychotic illness, severe personality disorder, or other significant psychiatric disorder other than depression related to MS/MS-associated spasticity.

5. Any known or suspected history of substance abuse/dependence disorder (including opiate abuse),current heavy alcohol consumption, current use of illicit drug, or current non-prescribed use of any prescription drug.

6. Poorly controlled epilepsy or recurrent seizures (i.e., one or more seizures in the past year).

7. Known or suspected hypersensitivity to cannabinoids or to any of the excipients of the study drugs.

8. Myocardial infarction or clinically significant cardiac dysfunction within 12 months of study entry or a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction

9. Female patients of child-bearing potential and male patients whose partner is of childbearing potential, unless willing to ensure that they or their partner use effective contraception throughout the study and for three months thereafter

10. Female patient who is pregnant, lactating, or planning pregnancy during the course of the study or within the 3 months thereafter.

11. Any other significant diseases or disorder, which, in the opinion of the investigator, participation in the study may either put the patient at risk or may influence the result of the study, or the patient's ability to participate in the study.

12. Travel outside the country planned during the study.

13. Unwilling to abstain from donating blood during the study.

14. Patients previously randomized into a cannabinoid-based clinical trial for MS pain and spasticity within 6 months of study entry.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PTL201
Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
Placebo Oral Capsule
Placebo seamless gelatin matrix green beads containing excipients only

Locations

Country Name City State
Israel Sheba medical center Tel Hashomer, Ramat gan

Sponsors (1)

Lead Sponsor Collaborator
PhytoTech Therapeutics, Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other Combined modified Ashworth score (cMAS) and MS walking scale 12 (MSWS-12) assessments, posturography measure, Selected spatio-temporal parameters of gait at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Primary Incidence of study treatment-related adverse events (AE) 10 weeks (70 days) from beginning of treatment to end of follow-up
Primary Change in sNRS scores from randomization to end of placebo-controlled treatment phase during the 4 weeks (28 days) placebo-controlled treatment period
Secondary Incidence of all AEs during 10 week treatment plus follow up period
Secondary Percent change in walking velocity during 4 weeks placebo-controlled treatment period
Secondary Clinical Global Impression Improvement (CGI-I) assessment using a 7-point scale condition at randomization (day 29) and the end of placebo-controlled treatment phase (day 57)
Secondary Cadence (steps/min) assessment at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary Stride length (cm) assessment at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary pNRS assessment at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary Spasm frequency assessment at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary Sleep disturbance assessment at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary Assessment of clinical gait measures Timed (sec) 25 foot walk test (T25FW) at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary Assessment of clinical gait measures Timed (sec) up and go test (TUG) at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis